// App-Quantinova.ai

4020 : Inhibition of KIT in vivo modifies immune cell populations to improve the efficacy of checkpoint inhibitors in syngeneic mouse tumor models

Researchers

Presenter

  • Andrew J. Garton

Principal Investigators

  • Lori Lopresti-Morrow

  • Scott Seibel

  • Theresa LaVallee

  • Richard Gedrich

Medical Centers

  • Kolltan Pharmaceuticals, New Haven, CT

Locations

  • United States

Companies

  • Kolltan Pharmaceutic

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neurofibromatosis type 1

  • Solid malignancies

  • Gastrointestinal stromal tumor

Biomarkers

  • Hepatocyte growth factor receptor

  • Neurofibromatosis type 1

Drug/Treatment

  • Anti-CTLA4

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved